Beneficial role of telmisartan on cardiovascular complications associated with STZ-induced type 2 diabetes in rats

Aeibi, 1974, Methods in Enzymatic Analysis, 2nd edn, 673 Alexander, 1994, Inflammation and coronary artery disease, N Engl J Med, 331, 468, 10.1056/NEJM199408183310709 Asbun, 2005, Profibrotic influence of high glucose concentration on cardiac fibroblast functions: effects of losartan and vitamin E, Am J Physiol Heart Circ Physiol, 288, H227, 10.1152/ajpheart.00340.2004 Beckman, 2002, Diabetes and atherosclerosis: epidemiology, pathophysiology, and management, Jama, 287, 2570, 10.1001/jama.287.19.2570 Benson, 2004, Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity, Hypertension, 43, 993, 10.1161/01.HYP.0000123072.34629.57 Berger, 2002, The mechanisms of action of PPARs, Annu Rev Med, 53, 409, 10.1146/annurev.med.53.082901.104018 Berry, 2000, Investigation into the sources of superoxide in human blood vessels, angiotensin II increases superoxide production in human internal mammary arteries, Circulation, 101, 2206, 10.1161/01.CIR.101.18.2206 Beutler, 1963, Reduced glutathione estimation, J Lab Clin Med, 61, 882 Bhakdi, 1999, Complement and atherogenesis. Binding of CRP to degraded, nonoxidised LDL enhance complement activation, Arterioscler Thromb Vasc Biol, 19, 2348, 10.1161/01.ATV.19.10.2348 Bonora, 1983, Decreased hepatic insulin excretion in subjects with mild glucose intolerance, Metabolism, 32, 438, 10.1016/0026-0495(83)90004-5 Brilla, 1995, Role of angiotensin II and prostaglandin E2 in regulating cardiac fibroblast collagen turnover, Am J Cardiol, 76, 8D, 10.1016/S0002-9149(99)80485-8 Carr, 1985, Detection of hyper-tensive left ventricular hypertrophy, Hypertension, 7, 948, 10.1161/01.HYP.7.6.948 Chase, 2004, Elevated C-reactive protein levels in the development of type 1 diabetes, Diabetes, 53, 2569, 10.2337/diabetes.53.10.2569 Dahm, 2005, Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes, J Hypertens, 23, 463, 10.1097/01.hjh.0000160198.05416.72 de Beer, 1982, Measurement of serum C-reactive protein concentration in myocardial ischaemia and infarction, Br Heart J, 47, 239, 10.1136/hrt.47.3.239 Devereux, 2000, Impact of diabetes on cardiac structure and function: the strong heart study, Circulation, 101, 2271, 10.1161/01.CIR.101.19.2271 Evans, 2005, The molecular basis for oxidative stress-induced insulin resistance, Anti-oxid Redox Signal, 7, 1040, 10.1089/ars.2005.7.1040 Fujimoto, 2000, The importance of insulin resistance in the pathogenesis of type 2 diabete mellitus, Am J Med, 108, 9S, 10.1016/S0002-9343(00)00337-5 Funakawa, 1983, Renin angiotensin system and prostacyclin biosynthesis in STZ diabetic rats, Eur J Pharmacol, 94, 27, 10.1016/0014-2999(83)90438-7 Goebel, 2006, Effective treatment of hypertension by AT 1 receptor antagonism: the past and future of telmisartan, Expert Rev Cardiovasc Ther, 4, 615, 10.1586/14779072.4.5.615 Goyal, 2008, Effect of telmisartan on cardiovascular complications associated with STZ-diabetic rats, Mol Cell Biochem, 314, 123, 10.1007/s11010-008-9772-y Goyal, 2009, Investigation into the cardiac effects of spironolactone in the experimental model of type 1 diabetes, J Cardiovasc Pharmacol, 54, 502, 10.1097/FJC.0b013e3181be75cc Goyal, 1999, Hyperinsulinemia and insulin resistance in hypertension: Differential effects of antihypertensive agents, Clin Exper Hypertens, 21, 167, 10.3109/10641969909068659 Gress, 2000, Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus: Atherosclerosis risk in communities study, N Engl J Med, 342, 905, 10.1056/NEJM200003303421301 Huang, 2006, Homocysteine and other biochemical parameters in type 2 diabetes mellitus with different diabetic duration or diabetic retinopathy, Clin Chim Acta, 366, 293, 10.1016/j.cca.2005.10.025 Ilercil, 2002, Associations of insulin levels with left ventricular structure and function in American Indians: the strong heart study, Diabetes, 51, 1543, 10.2337/diabetes.51.5.1543 Inoguchi, 2000, High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells, Diabetes, 49, 1939, 10.2337/diabetes.49.11.1939 Jesmin, 2003, Role of angiotensin II in altered expression of molecules responsible for coronary matrix remodeling in insulin-resistant diabetic rats, Arterioscler Thromb Vasc Biol, 23, 2021, 10.1161/01.ATV.0000094235.78783.D1 Kadoglou, 2005, Matrix metalloproteinases and diabetic vascular complications, Angiology, 56, 173, 10.1177/000331970505600208 Kakuta, 2005, Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor blockers, Int J Clin Pharm Res, 25, 41 Kamari, 2008, Effect of telmisartan, angiotensin II receptor antagonist, on metabolic profile in fructose-induced hypertensive, hyperinsulinemic, hyperlipidemic rats, Hypertens Res, 31, 135, 10.1291/hypres.31.135 Kawano, 2000, Angiotensin II has multiple profibrotic effects in human cardiac fibroblasts, Circulation, 101, 1130, 10.1161/01.CIR.101.10.1130 Kuhn, 1991, Effects of high-density lipoprotein on acetylcholine induced coronary vasoreactivity, Am J Cardiol, 68, 1425, 10.1016/0002-9149(91)90274-O Lang, 2000, Coronary microvascular endothelial cell redox state in left ventricular hypertrophy: the role of angiotensin II, Circ Res, 86, 463, 10.1161/01.RES.86.4.463 Li, 1999, Upregulation of endothelial receptor for oxidized low-density lipoprotein (LOX-1) in cultured human coronary artery endothelial cells by angiotensin II type 1 receptor activation, Circ Res, 84, 1043, 10.1161/01.RES.84.9.1043 Liu, 2001, The impact of diabetes on left ventricular filling pattern in normotensive and hyper-tensive adults: the strong heart study, J Am Coll Cardiol, 37, 1943, 10.1016/S0735-1097(01)01230-X Lorell, 1999, Role of angiotensin AT1 and AT2 receptors in cardiac hypertrophy and disease, Am J Cardiol, 83, 48, 10.1016/S0002-9149(99)00258-1 Malmqvist, 2001, Regression of left ventricular hypertrophy in human hypertension with irbesartan, J Hypertens, 19, 1167, 10.1097/00004872-200106000-00023 Martina, 2003, Effects of telmisartan and losartan on left ventricular mass in mild-to-moderate hypertension: a randomized, double-blind trial, Cardiology, 99, 169, 10.1159/000070675 Misra, 1984, The role of superoxide anion autoxidation of epinephrine and a simple method for su-peroxide dismutase, J Biol Chem, 247, 3170, 10.1016/S0021-9258(19)45228-9 Mizushige, 2000, Alteration in left ventricular diastolic filling and accumulation of myocardial collagen at insulin-resistant prediabetic stage of a type II diabetic rat model, Circulation, 101, 899, 10.1161/01.CIR.101.8.899 Nakamura, 1998, Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-α and angiotensin II, Circulation, 98, 794, 10.1161/01.CIR.98.8.794 Ohkawa, 1979, Assay for lipid peroxides in animal tissue by thiobarbituric acid reaction, Anal Biochem, 95, 351, 10.1016/0003-2697(79)90738-3 Oliveira, 1996, Changes in the baroreflex control of heart rate produced by central infusion of selective angiotensin antagonists in hypertensive rats, Hyper-tension, 27, 1284, 10.1161/01.HYP.27.6.1284 ONTARGET Investigators Telmisartan, ramipril, or both in patients at high risk for vascular events. New Engl J Med, 2008, 358, 1547-1559. Pershadsingh, 2003, Identification of PPAR-γ activators that do not promote fluid retention and edema: implications for treating insulin resistant hypertension and the metabolic syndrome, In: Proceedings of the Endocrine Society Symposium on Nuclear Receptors in Cardiovascular Disease, Hot Topics in Endocrinology Petrovic, 2005, Ventricular and vascular remodelling effects of the angiotensin II receptor blocker telmisartan and/or the angiotensin-converting enzyme inhibitor ramipril in hypertensive patients, J Int Med Res, 33, 39A, 10.1177/14732300050330S106 Portha, 1979, Chemical diabetes in the adult rats as the spontaneous evolution of neonatal diabetes, Diabetologia, 17, 371, 10.1007/BF01236272 Pradhan, 2001, C-reactive protein, interleukin-6, and risk of developing type 2 diabetes mellitus, Jama, 286, 327, 10.1001/jama.286.3.327 Prockop, 1960, A specific method for the analysis of hydroxyproline in tissues and urine, Anal Biochem, 1, 228, 10.1016/0003-2697(60)90050-6 Rahimi, 2005, A review on the role of antioxidants in the management of diabetes and its complications, Biomed Pharmacother, 59, 365, 10.1016/j.biopha.2005.07.002 Rani, 2003, Serum adeno-sine deaminase activity and C-reactive protein levels in unstable angina, Indian J Hum Gen, 9, 17 Roberts, 1978, Creatine kinase isoenzymes in the assessment of heart disease, Am Heart J, 95, 521, 10.1016/0002-8703(78)90245-4 Setaro, 2001, The hypertensive heart: new observations and evolving therapeutic imperatives, J Clin Hypertens (Greenwich), 3, 14, 10.1111/j.1524-6175.2001.00825.x Sheen, 2004, Prevention of type 2 diabetes mellitus through inhibition of the renin-angiotensin system, Drugs, 64, 2537, 10.2165/00003495-200464220-00004 Smits, 1992, Angiotensin II receptor blockade after myocardial infarction in rats: effects on hemodynamics, myocardial DNA synthesis, and interstitial collagen content, J Cardiovasc Pharmacol, 20, 772 Sowers, 2001, Diabetes, hypertension, and cardiovascular disease: an update, Hypertension, 37, 1053, 10.1161/01.HYP.37.4.1053 Sowers, 1990, Clinical implications of hyper-tension in the diabetic patient: A review, Am J Hyper-tens, 3, 415, 10.1093/ajh/3.5.415 Stehouwer, 1996, The pathogenesis of vascular complications of diabetes mellitus: one voice or many?, Eur J Clin Invest, 26, 535, 10.1046/j.1365-2362.1996.1780527.x Sun, 1995, Angiotensin II, transforming growth factor-β1 and repair in the infarcted heart, J Mol Cell Cardiol, 30, 1559, 10.1006/jmcc.1998.0721 Takenaka, 2006, Angiotensin II, oxidative stress, and extracellular matrix degradation during transition to LV failure in rats with hypertension, J Mol Cell Cardiol, 41, 989, 10.1016/j.yjmcc.2006.07.019 Telmisartan Randomised Assessment Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators: Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ van Harsdorf R, Li PF, Dietz R: Signalling pathways in reactive oxygen species-induced cardiomyocyte apoptosis. Circulation Wang, 2003, Characterization of cardiac hypertrophy and heart failure due to volume overload in the rat, J Appl Physiol, 94, 752, 10.1152/japplphysiol.00248.2002 Weber, 1995, Structural remodelling of the heart by fibrous tissue: Role of circulating hormones and local produced peptides, Eur Heart J, 16, 12, 10.1093/eurheartj/16.suppl_N.12 Weir, 1999, Diabetes and hypertension: blood pressure control and consequences, Am J Hypertens, 12, 170S, 10.1016/S0895-7061(99)00219-8 Yamauchi, 2001, The mechanisms by which both heterozygous peroxisome proliferator-activated receptor γ (PPARγ) deficiency and PPARγ agonist improve insulin resistance, J Biol Chem, 276, 41245, 10.1074/jbc.M103241200 Yoshida, 2006, Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferators activated receptor-gamma activation, Diabetologia, 49, 3094, 10.1007/s00125-006-0437-7 Zhang, 2007, Role of AT1 receptor in isoproterenol-induced cardiac hypertrophy and oxidative stress in mice, J Mol Cell Cardiol, 42, 804, 10.1016/j.yjmcc.2007.01.012 Zhang, 2005, Pentoxifylline attenuates cardiac dysfunction and reduces TNF-α level in ischemic-reperfused heart, Am J Physiol Heart Circ Physiol, 289, H832, 10.1152/ajpheart.00178.2005 Zhao, 2006, ANG II-induced cardiac molecular and cellular events: role of aldosterone, Am J Physiol Heart Circ Physiol, 291, H336, 10.1152/ajpheart.01307.2005 Zile, 2002, New concepts in diastolic dys-function and diastolic heart failure. Part II. Causal mechanisms and treatment, Circulation, 105, 1503, 10.1161/hc1202.105290 Zou, 2009, Telmisartan versus angiotension-converting enzyme inhibitors in the treatment of hypertension: a meta-analysis of randomized controlled trials, J Hum Hypertens, 23, 339, 10.1038/jhh.2008.132